ClearPoint Neuro, Inc. is a medical technology firm primarily operating within the United States. The company specializes in developing and commercializing sophisticated systems that facilitate minimally invasive brain surgeries, guided by real-time magnetic resonance imaging (MRI) during the procedure. Among its core offerings is the ClearPoint system, designed for the precise placement of deep brain stimulation electrodes, biopsy needles, and for the controlled infusion of medications and laser catheters directly into the brain. It also provides the ClearPoint Neuro Navigation System, which is specifically engineered for MRI suite environments. ClearPoint Neuro maintains strategic partnerships and licensing agreements with prominent institutions and companies, including Boston Scientific Corporation, The Johns Hopkins University, Clinical Laserthermia Systems Americas Inc, Koninklijke Philips N.V., Blackrock Neurotech, and the University of California, San Francisco. Initially established in 1998 and headquartered in Solana Beach, California, the company operated as MRI Interventions, Inc. before rebranding to ClearPoint Neuro, Inc. in February 2020.

Employees - 115, CEO - Joseph Michael Burnett, Sector - Healthcare, Country - US, Market Cap -

Altman ZScore(max is 10): -0.05, Piotroski Score(max is 10): 3, Working Capital: $45397000, Total Assets: $93416000, Retained Earnings: $-226462000, EBIT: -26313000, Total Liabilities: $74575000, Revenue: $40614000

AryaFin Target Price - $-10.61 - Current Price $ - Analyst Target Price $